Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Merck
AstraZeneca
QuintilesIMS
Healthtrust
Express Scripts
Dow
Federal Trade Commission
Cerilliant
Baxter

Generated: January 21, 2018

DrugPatentWatch Database Preview

PRISTIQ Drug Profile

« Back to Dashboard

Which patents cover Pristiq, and what generic alternatives are available?

Pristiq is a drug marketed by Wyeth Pharms Inc and is included in one NDA. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has sixty-eight patent family members in thirty-two countries.

The generic ingredient in PRISTIQ is desvenlafaxine succinate. There are sixteen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the desvenlafaxine succinate profile page.

US Patents and Regulatory Information for PRISTIQ

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms Inc PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-003 Aug 20, 2014 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Wyeth Pharms Inc PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-002 Feb 29, 2008 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Wyeth Pharms Inc PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-001 Feb 29, 2008 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Wyeth Pharms Inc PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-002 Feb 29, 2008 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Wyeth Pharms Inc PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-003 Aug 20, 2014 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Wyeth Pharms Inc PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-001 Feb 29, 2008 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for PRISTIQ
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Extended-release Tablets 25 mg ➤ Subscribe 5/8/2015
➤ Subscribe Extended-release Tablets 50 mg and 100 mg ➤ Subscribe 2/29/2012

Non-Orange Book US Patents for PRISTIQ

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,026,508 Succinate salt of O-desmethyl-venlafaxine ➤ Subscribe
7,291,347 Succinate salt of O-desmethyl-venlafaxine ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for PRISTIQ

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Covington
Cipla
McKesson
AstraZeneca
Federal Trade Commission
Johnson and Johnson
Healthtrust
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot